New Data Demonstrates Talabostat's Anti-Tumor and Anti-Metastatic Properties in Preclinical Osteosarcoma Models
30 October 2006 - 11:50PM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) presented new data in an
osteosarcoma model demonstrating that mice treated with talabostat
had a four- fold decrease in the number of primary tumors compared
to saline treatment. In a separate experiment in the study, mice
treated with talabostat had a 20-fold decrease in the number of
gross metastatic lung nodules compared to saline treatment. The
studies, conducted in the laboratory of Dr. Lee J. Helman, in the
Pediatric Oncology Branch of the National Institutes of Health,
were presented at the 21st Annual Meeting of the International
Society for Biological Therapy of Cancer (iSBTC) Development in Los
Angeles, CA this past Saturday. Osteosarcoma is the most common
pediatric bone cancer in the United States. According to a 2002
article in the Journal of Oncology, advances in surgery and
chemotherapy have led to cure rates approaching 70% for children
who present with localized disease. However, children who present
with metastatic disease have only a 20% survival rate. In one
experiment, talabostat was shown to decrease the growth of primary
tumors. Mice were injected intramuscularly with a murine
osteosarcoma cell line and treatment with either talabostat or
saline began the following day. Mice treated with talabostat had a
marked reduction in the development of primary tumors. Only two out
of 10 mice treated with talabostat went on to form tumors whereas
eight out 10 mice treated with saline formed tumors. In a separate
experiment, mice were injected in the tail vein with the murine
osteosarcoma cell line to assess talabostat�s anti-metastatic
properties. Post injection, mice were treated with either
talabostat or saline. After 24 days, mice treated with talabostat
had a 20-fold decrease in the number of gross metastatic lung
nodules compared to the control group (p
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles